Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma
To study the clinical significance of serum epidermal growth factor receptor (EGFR) gene mutation and serum tumor markers in the prediction of tyrosine kinase inhibitor (TKI) efficacy in patients with lung adenocarcinoma.
Ninety patients with pathologically diagnosed lung adenocarcinoma were enrolled. Further, 51 out of 90 patients received the EGFR-TKI therapy, oral gefitinib. The correlations among serum EGFR gene mutations in exons 18–21, serum tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 24-2 (CA24-2), carbohydrate antigen 125, carbohydrate antigen 15-3 as well as carbohydrate antigen 19-9 (CA19-9) levels, and EGFR-TKI efficacy were determined.
There was a high consistency of EGFR gene mutation rate between serum and tissue samples. The serum EGFR gene mutation rate in female patients or non-smokers was significantly higher than that in male patients or smokers, respectively. Serum CA19-9, CA24-2, and CEA levels were significantly correlated with serum EGFR mutation. After receiving gefitinib, the progression-free survivals (PFSs) of patients with high serum CEA level, high serum CA19-9 level, or serum EGFR gene mutation were significantly higher than those of normal patients, respectively. The PFSs were significantly prolonged in patients with EGFR gene mutation and high serum CEA level or patients with EGFR gene mutation and high serum CA19-9 level compared with those in patients with one abnormal biomarker and normal patients.
Combined detection of EGFR gene mutations as well as CA19-9 and CEA levels in peripheral blood can predict the efficacy of EGFR-TKI in the treatment of patients with lung adenocarcinoma.
KeywordsLung adenocarcinoma Epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) Carcinoembryonic antigen (CEA) Carbohydrate antigen 19-9 (CA19-9) Serum tumor marker
Compliance with ethical standards
Conflict of interest
All authors declare that there is no conflict of interest.
This study was approved by the Ethics Committee of The Affiliated Hospital of Qingdao University.
The written informed consent was obtained from all the patients.
- 4.Cha YK, et al. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Lung Cancer. 2015;16(3):228–36.CrossRefGoogle Scholar
- 8.Ma C, Wei S, Song Y. T790 M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2011;3(1):10–8.Google Scholar
- 11.Chabot-Richards D, Buehler K, Vasef MA. Detection of epidermal growth factor receptor (EGFR) exon 19 E746-A750 deletion and EGFR exon 21 point mutations in lung adenocarcinoma by immunohistochemistry: a comparative study to EGFR exons 19 and 21 mutations analysis using PCR followed by high-resolution melting and pyrosequencing. J Histotechnol. 2015;38(2):56–62.CrossRefGoogle Scholar
- 12.Hyun MH, et al. Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer. Oncotarget. 2017;8(55):94417–30.Google Scholar
- 30.Ma G, et al. Epidermal growth factor receptor T790 M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget. 2017;8(59):99429–37.Google Scholar
- 34.Fan MJ, et al. Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi. 2011;40(10):679–82.Google Scholar
- 42.Kimura T, et al. Phase II study of carboplatin and pemetrexed in advanced EGFR-wild-type non-squamous non-small cell lung cancer: the central japan lung study group trial 0906. Anticancer Res. 2016;36(4):1767–71.Google Scholar
- 45.Chen F, et al. Diagnostic value of CYFRA 21-1 and CEA for predicting lymph node metastasis in operable lung cancer. Int J Clin Exp Med. 2015;8(6):9820–4.Google Scholar
- 46.Takeuchi A, et al. Predictive and prognostic value of CYFRA 21-1 for advanced non-small cell lung cancer treated with EGFR-TKIs. Anticancer Res. 2017;37(10):5771–6.Google Scholar